Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Telisotuzumab vedotin |
Trade Name | |
Synonyms | ABBV-399|Teliso-V |
Drug Descriptions |
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET expressing tumor cells, resulting in cell death (PMID: 27573171, PMID: 32127466). |
DrugClasses | MET Antibody 31 |
CAS Registry Number | 1781223-80-0 |
NCIT ID | C118571 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Telisotuzumab vedotin | Bevacizumab Telisotuzumab vedotin | 0 | 1 |
Carboplatin + Telisotuzumab vedotin | Carboplatin Telisotuzumab vedotin | 0 | 1 |
Cetuximab + Telisotuzumab vedotin | Cetuximab Telisotuzumab vedotin | 0 | 1 |
Erlotinib + Telisotuzumab vedotin | Erlotinib Telisotuzumab vedotin | 0 | 1 |
Osimertinib + Telisotuzumab vedotin | Osimertinib Telisotuzumab vedotin | 0 | 0 |
Telisotuzumab vedotin | Telisotuzumab vedotin | 0 | 6 |